Generation of cytotoxicity against hepatitis delta virus genotypes and quasispecies by epitope modification

Journal of Hepatology

Volumn 50, Issue 4, 2009, Pages 779-788

  Huang, Yi Hsiang ^a,b   Wu, Jaw Ching ^a,b   Peng, Wei Li ^a   Huo, Teh Ia ^a,b   Shih, Hsuan Hui ^b   Lan, Keng Hsin ^a,b   Su, Chien Wei ^a,b   Lee, Shou Dong ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cytotoxic T cells; Epitope; HDV; Hepatitis; Quasispecies

Indexed keywords

ALANINE; DNA VACCINE; EPITOPE; GAMMA INTERFERON; HEPATITIS DELTA ANTIGEN; HLA A2 ANTIGEN; PLASMID DNA; T LYMPHOCYTE RECEPTOR; TYROSINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO ACID SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL MEDIATED CYTOTOXICITY; CELL STRAIN HEPG2; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DELTA AGENT HEPATITIS; DNA IMMUNIZATION; DNA MODIFICATION; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS DELTA VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; GENE AMPLIFICATION; GENES, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS C; HEPATITIS D; HEPATITIS DELTA ANTIGENS; HEPATITIS DELTA VIRUS; HLA-A2 ANTIGEN; HUMANS; MICE; MUTANT CHIMERIC PROTEINS; PEPTIDES; PLASMIDS;

EID: 61749090522     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.11.028     Document Type: Article

References (47)

1. Rizzetto M., Canese M.G., Gerin J.L., London W.T., Sly D.L., and Purcell R.H. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis 141 (1980) 590-602
2. Taylor J.M. Hepatitis delta virus. Virology 344 (2006) 71-76
3. Govindarajan S., De Cock K.M., and Redeker A.G. Natural course of delta superinfection in chronic hepatitis B virus-infected patients: histopathologic study with multiple liver biopsies. Hepatology 6 (1986) 640-644
4. Wu J.C., Chen T.Z., Huang Y.S., Yen F.S., Ting L.T., Sheng W.Y., et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 108 (1995) 796-802
5. Wu J.C., Chen C.L., Hou M.C., Chen T.Z., Lee S.D., and Lo K.J. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitations of the polymerase chain reaction. Hepatology 19 (1994) 836-840
6. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
7. Farci P. Delta hepatitis: an update. J Hepatol 39 Suppl. 1 (2003) S212-S219
8. Farci P., Roskams T., Chessa L., Peddis G., Mazzoleni A.P., Scioscia R., et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 126 (2004) 1740-1749
9. Niro G.A., Ciancio A., Gaeta G.B., Smedile A., Marrone A., Olivero A., et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44 (2006) 713-720
10. Castelnau C., Le Gal F., Ripault M.P., Gordien E., Martinot-Peignoux M., Boyer N., et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 44 (2006) 728-735
11. Maini M.K., Boni C., Lee C.K., Larrubia J.R., Reignat S., Ogg G.S., et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191 (2000) 1269-1280
12. Chisari F.V., and Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13 (1995) 29-60
13. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., and Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25 (1997) 449-458
14. *0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. J Gen Virol 85 (2004) 3089-3098
15. Huang Y.H., Wu J.C., Tao M.H., Syu W.J., Hsu S.C., Chi W.K., et al. DNA-based immunization produces Th1 immune responses to hepatitis delta virus in a mouse model. Hepatology 32 (2000) 104-110
16. Huang Y.H., Wu J.C., Hsu S.C., and Syu W.J. Varied immunity generated in mice by DNA vaccines with large and small hepatitis delta antigens. J Virol 77 (2003) 12980-12985
17. Fiedler M., Lu M., Siegel F., Whipple J., and Roggendorf M. Immunization of woodchucks (Marmota monax) with hepatitis delta virus DNA vaccine. Vaccine 19 (2001) 4618-4626
18. Casey J.L., Tennant B.C., and Gerin J.L. Genetic changes in hepatitis delta virus from acutely and chronically infected woodchucks. J Virol 80 (2006) 6469-6477
19. Wang S.Y., Wu J.C., Chiang T.Y., Huang Y.H., Su C.W., and Sheen I.J. Positive selection of hepatitis delta antigen in chronic hepatitis D patients. J Virol 81 (2007) 4438-4444
20. Chang J., Gudima S.O., and Taylor J.M. Evolution of hepatitis delta virus RNA genome following long-term replication in cell culture. J Virol 79 (2005) 13310-13316
21. Radjef N., Gordien E., Ivaniushina V., Gault E., Anais P., Drugan T., et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 78 (2004) 2537-2544
22. Le Gal F., Gault E., Ripault M.P., Serpaggi J., Trinchet J.C., Gordien E., et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis 12 (2006) 1447-1450
23. Casey J.L., Brown T.L., Colan E.J., Wignall F.S., and Gerin J.L. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci USA 90 (1993) 9016-9020
24. Wu J.C., Chen C.M., Sheen I.J., Lee S.D., Tzeng H.M., and Choo K.B. Evidence of transmission of hepatitis D virus to spouses from sequence analysis of the viral genome. Hepatology 22 (1995) 1656-1660
25. Wu J.C., Chiang T.Y., and Sheen I.J. Characterization and phylogenetic analysis of a novel hepatitis D virus strain discovered by restriction fragment length polymorphism analysis. J Gen Virol 79 Pt 5 (1998) 1105-1113
26. Berzofsky J.A., Ahlers J.D., Janik J., Morris J., Oh S., Terabe M., et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114 (2004) 450-462
27. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006) 682-687
28. Berzofsky J.A., Ahlers J.D., and Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1 (2001) 209-219
29. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., and Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185 (1997) 2043-2051
30. Firat H., Tourdot S., Ureta-Vidal A., Scardino A., Suhrbier A., Buseyne F., et al. Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. Eur J Immunol 31 (2001) 3064-3074
31. Sarobe P., Pendleton C.D., Akatsuka T., Lau D., Engelhard V.H., Feinstone S.M., et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest 102 (1998) 1239-1248
32. Nijman H.W., Houbiers J.G., Vierboom M.P., van der Burg S.H., Drijfhout J.W., D'Amaro J., et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 23 (1993) 1215-1219
33. Okazaki T., Pendleton C.D., Lemonnier F., and Berzofsky J.A. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. J Immunol 171 (2003) 2548-2555
34. Ruppert J., Sidney J., Celis E., Kubo R.T., Grey H.M., and Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74 (1993) 929-937
35. Pogue R.R., Eron J., Frelinger J.A., and Matsui M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc Natl Acad Sci USA 92 (1995) 8166-8170
36. Tourdot S., Scardino A., Saloustrou E., Gross D.A., Pascolo S., Cordopatis P., et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 30 (2000) 3411-3421
37. Alexander-Miller M.A., Leggatt G.R., and Berzofsky J.A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 93 (1996) 4102-4107
38. Gallimore A., Dumrese T., Hengartner H., Zinkernagel R.M., and Rammensee H.G. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 187 (1998) 1647-1657
39. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4 (1998) 321-327
40. Bertoletti A., Sette A., Chisari F.V., Penna A., Levrero M., De Carli M., et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369 (1994) 407-410
41. Wu J.C., Choo K.B., Chen C.M., Chen T.Z., Huo T.I., and Lee S.D. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 346 (1995) 939-941
42. Su C.W., Huang Y.H., Huo T.I., Shih H.H., Sheen I.J., Chen S.W., et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 130 (2006) 1625-1635
43. Karayiannis P., Saldanha J., Monjardino J., Goldin R., Main J., Luther S., et al. Immunization of woodchucks with recombinant hepatitis delta antigen does not protect against hepatitis delta virus infection. Hepatology 12 (1990) 1125-1128
44. Karayiannis P., Saldanha J., Jackson A.M., Luther S., Goldin R., Monjardino J., et al. Partial control of hepatitis delta virus superinfection by immunisation of woodchucks (Marmota monax) with hepatitis delta antigen expressed by a recombinant vaccinia or baculovirus. J Med Virol 41 (1993) 210-214
45. Fiedler M., and Roggendorf M. Vaccination against hepatitis delta virus infection: studies in the woodchuck (Marmota monax) model. Intervirology 44 (2001) 154-161
46. Nisini R., Paroli M., Accapezzato D., Bonino F., Rosina F., Santantonio T., et al. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J Virol 71 (1997) 2241-2251
47. D'Ugo E., Paroli M., Palmieri G., Giuseppetti R., Argentini C., Tritarelli E., et al. Immunization of woodchucks with adjuvanted sHDAg (p24): immune response and outcome following challenge. Vaccine 22 (2004) 457-466